AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
PFA herewith intimation w.r.t loss of share certificates27-09-2023
27-09-2023
AJANTA PHARMA LTD. - 532331 - Business Responsibility and Sustainability Reporting (BRSR)
PFA herewith BRSR for FY 2023.21-09-2023
AJANTA PHARMA LTD. - 532331 - Reply To Clarification Sought By BSE
Pl. find attached herewith Company''s reply w.r.t. clarification sought by BSE.15-09-2023
AJANTA PHARMA LTD. - 532331 - Clarification sought from Ajanta Pharma Ltd
The Exchange has sought clarification from Ajanta Pharma Ltd on September 14, 2023, with reference to Movement in Volume.The reply is awaited.14-09-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
PFA herewith newspaper publication w.r.t. transfer of shares to IEPF.04-09-2023
Ajanta Pharma rises on USFDA nod for Topiramate capsules
The share touched a 52-week high of Rs 1,804.70 and a 52-week low of Rs 1,115.15 on 17 August, 2023 and 28 October, 2022, respectively.31-08-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
PFA herewith Press Release.30-08-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 25, 2023 for Ravi Agrawal, Trustee Ravi Agrawal Trust25-08-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 24, 2023 for Ravi Agrawal, trustee Ravi Agrawal Trust24-08-2023